{"id":946366,"date":"2026-03-23T16:09:11","date_gmt":"2026-03-23T20:09:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/"},"modified":"2026-03-23T16:09:11","modified_gmt":"2026-03-23T20:09:11","slug":"nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/","title":{"rendered":"Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting"},"content":{"rendered":"
\n

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that two oral presentations and three poster presentations highlighting the breadth of its research pipeline and scientific leadership will be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting, to be held April 17-22, 2026, in San Diego, California.<\/p>\n

The presentations will provide additional mechanistic validation of CBL-B, Aurora kinase A (AURKA) and mutant BRAF as therapeutic targets across multiple cancer indications and will highlight the potential of Nurix\u2019s orally bioavailable degraders to effectively suppress the oncogenic activity of these proteins in preclinical models.<\/p>\n

Additionally, Gwenn Hansen, Ph.D., chief scientific officer of Nurix Therapeutics, has been selected to speak in an AACR Advances session on induced proximity pharmacology, including targeted protein degradation. AACR Advances sessions bring together leading scientific perspectives to provide a comprehensive view of recent developments, the current state of research, and emerging challenges in the field.<\/p>\n

\n
\n Oral Presentation Details: <\/u>
\n <\/strong>\n <\/p>\n

\n Title: <\/strong>Designing Effective Degrader Therapeutics: What Early Clinical Experience Has Taught Us
Speaker: <\/strong>Gwenn Hansen, Ph.D., chief scientific officer, Nurix Therapeutics
Session type: <\/strong>Advances in Diagnostics and Therapeutics
Session title: <\/strong>Induced Proximity Pharmacology: Degraders and Beyond
Session date and time: <\/strong>Wednesday, April 22, 2026, 10:15 a.m. \u2013 11:45 a.m. PT<\/p>\n

\n Title: <\/strong>Discovery and characterization of CBL-B intramolecular glue inhibitors that increase T cell activation and suppress tumor growth
Presenter: <\/strong>Fred Cohen, Ph.D.
Session type: <\/strong>Minisymposium
Session category:<\/strong> Chemistry
Session title: <\/strong>Targeted Therapies
Session date and time: <\/strong>Tuesday, April 21, 2026, 4:30 p.m. PT
Abstract presentation #:<\/strong> 6733<\/p>\n

\n
\n Poster Presentation Details:<\/u>
\n <\/strong>\n <\/p>\n

\n Title: <\/strong>NRX-4972, a selective, oral, Aurora kinase A degrader, demonstrates increased efficacy in an SCLC tumor model, and greater in vitro synergy than an AURKA inhibitor
Presenting author: <\/strong>Ryan Rountree, Ph.D.
Session category:<\/strong> Targeted Protein Degradation and Induced Proximity
Session title: <\/strong>Targeted Protein Degradation and Induced Proximity
Session date and time: <\/strong>Tuesday, April 21, 2026, 9:00 a.m. \u2013 12:00 p.m. PT
Poster #: <\/strong>5166<\/p>\n

\n Title: <\/strong>NRX-0305, an orally bioavailable, CNS penetrant pan-mutant BRAF degrader demonstrates robust efficacy in intracranial models of melanoma brain metastasis and primary glioma
Presenting author: <\/strong>Sasha Borodovsky, Ph.D.
Session category: <\/strong>Experimental and Molecular Therapeutics
Session title: <\/strong>Proximity-Induced Drug Discovery 1
Session date and time: <\/strong>Tuesday, April 21, 2026, 9:00 a.m. \u2013 12:00 p.m. PT
Poster #: <\/strong>4617<\/p>\n

\n Title: <\/strong>NRX-0305 is an orally bioavailable, pan-mutant BRAF degrader that exhibits single-agent and combination efficacy with MEKi or anti-EGFR across Class 1\/2\/3 BRAF-mutant cancers
Presenting author: <\/strong>Ya-Wen Lu, Ph.D.
Session category: <\/strong>Experimental and Molecular Therapeutics
Session title: <\/strong>Proximity-Induced Drug Discovery 2
Session date and time: <\/strong>Tuesday, April 21, 2026, 2:00 p.m. \u2013 5:00 p.m. PT
Poster #: <\/strong>5801<\/p>\n

\n About NX-1607<\/strong>
\n
NX-1607 is an investigational first-in-class oral inhibitor of the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CBL-B) being developed for immuno-oncology indications, including a range of solid tumor types. CBL-B is a cytoplasmic E3 ubiquitin ligase that negatively regulates T cell activation, making it an attractive target for immuno-oncology and offering a novel therapeutic approach to treat solid tumors. Inhibition of CBL-B in preclinical studies reverses T cell exhaustion, alleviates tumor induced immunosuppression, and may also exert direct antitumor effects. Nurix is evaluating NX-1607 in an ongoing Phase 1 trial in adults in a range of oncology indications. This study includes a thorough investigation of both dose and schedule in the Phase 1a portion. Additional information on the NX-1607 clinical trial can be accessed at www.clinicaltrials.gov (NCT05107674).<\/p>\n

\n About NRX-0305\u00a0<\/strong>
\n
NRX-0305\u00a0is a potent, selective, and orally bioavailable CNS-penetrant pan-mutant BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating potent anti-tumor activity in multiple cell line-derived and patient-derived xenograft disease models representing Class I, Class II, and Class III B-RAF mutations. Anti-tumor activity was also observed in the setting of CNS disease and treatment-resistance, suggesting the potential for utility across a broad range of solid tumor types.<\/p>\n

\n About NRX-4972<\/strong>
\n
NRX-4972 is a CNS-penetrant, orally bioavailable and highly selective degrader of Aurora A kinase (AURKA). AURKA is an oncogene frequently overexpressed in adult solid tumors, hematologic malignancies, and pediatric cancers. Several AURKA inhibitors are effective in\u00a0preclinical tumor models, but this activity has failed to translate into clinical efficacy. To address the limitations of inhibitors, Nurix has designed bifunctional targeted protein degraders of\u00a0AURKA that enable removal of both enzymatic and scaffolding functions.<\/p>\n

\n About Nurix Therapeutics, Inc.<\/strong>
\n
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix\u2019s wholly owned, clinical stage pipeline includes degraders of Bruton\u2019s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix\u2019s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6 in collaboration with Sanofi, a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix\u2019s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine\u2019s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http:\/\/www.nurixtx.com<\/u><\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding Nurix\u2019s intention to present preclinical data from multiple programs at the AACR 2026 Annual Meeting, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading \u201cRisk Factors\u201d in Nurix\u2019s Annual Report on Form 10-K for the fiscal year ended November 30, 2025, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix\u2019s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix\u2019s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Investors<\/strong>
\n
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com<\/u><\/a><\/p>\n

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com<\/u><\/a><\/p>\n

\n Media<\/strong>
\n
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com<\/u><\/a><\/p>\n

Kris Fortner
Nurix Therapeutics, Inc.
Kfortner@nurixtx.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that two oral presentations and three poster presentations highlighting the breadth of its research pipeline and scientific leadership will be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting, to be held April 17-22, 2026, in San Diego, California. The presentations will provide additional mechanistic validation of CBL-B, Aurora kinase A (AURKA) and mutant BRAF as therapeutic targets across multiple cancer indications and will highlight the potential of Nurix\u2019s orally bioavailable degraders to effectively suppress the oncogenic activity of these proteins in preclinical models. Additionally, Gwenn … <\/p>\n

Continue reading “Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-946366","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that two oral presentations and three poster presentations highlighting the breadth of its research pipeline and scientific leadership will be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting, to be held April 17-22, 2026, in San Diego, California. The presentations will provide additional mechanistic validation of CBL-B, Aurora kinase A (AURKA) and mutant BRAF as therapeutic targets across multiple cancer indications and will highlight the potential of Nurix\u2019s orally bioavailable degraders to effectively suppress the oncogenic activity of these proteins in preclinical models. Additionally, Gwenn … Continue reading "Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T20:09:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk4MCM3NDk5Mzk2IzIyMDA2Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting\",\"datePublished\":\"2026-03-23T20:09:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/\"},\"wordCount\":1224,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njk4MCM3NDk5Mzk2IzIyMDA2Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/\",\"name\":\"Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njk4MCM3NDk5Mzk2IzIyMDA2Njk=\",\"datePublished\":\"2026-03-23T20:09:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njk4MCM3NDk5Mzk2IzIyMDA2Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njk4MCM3NDk5Mzk2IzIyMDA2Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting - Market Newsdesk","og_description":"BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that two oral presentations and three poster presentations highlighting the breadth of its research pipeline and scientific leadership will be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting, to be held April 17-22, 2026, in San Diego, California. The presentations will provide additional mechanistic validation of CBL-B, Aurora kinase A (AURKA) and mutant BRAF as therapeutic targets across multiple cancer indications and will highlight the potential of Nurix\u2019s orally bioavailable degraders to effectively suppress the oncogenic activity of these proteins in preclinical models. Additionally, Gwenn … Continue reading \"Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-23T20:09:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk4MCM3NDk5Mzk2IzIyMDA2Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting","datePublished":"2026-03-23T20:09:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/"},"wordCount":1224,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk4MCM3NDk5Mzk2IzIyMDA2Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/","name":"Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk4MCM3NDk5Mzk2IzIyMDA2Njk=","datePublished":"2026-03-23T20:09:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk4MCM3NDk5Mzk2IzIyMDA2Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk4MCM3NDk5Mzk2IzIyMDA2Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=946366"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946366\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=946366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=946366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=946366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}